Merrimack anticipates the following upcoming milestones:
- Presentation of updated MM-398 Phase 3 NAPOLI-1 results at ASCO GI in
January 2015 ; - Submission of a New Drug Application to the
FDA for MM-398; - Announcement of top line data from the Phase 2 clinical trial of MM-111 in gastric, esophageal and gastroesophageal cancers in 2015; and
- Initiation of a Phase 2 clinical trial of MM-141 in front line pancreatic cancer in 2015.
